BioSante's CML vaccine gains orphan-drug status from FDA

06/7/2010 | International Business Times · Reuters

BioSante Pharmaceuticals said its experimental vaccine GVAX CML was granted orphan-drug designation by the FDA for treating patients with chronic myeloid leukemia. The drugmaker previously obtained orphan status for two other GVAX vaccines to treat pancreatic cancer and acute myeloid leukemia.

View Full Article in:

International Business Times · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Catheter Engineer Manager
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD